Literature DB >> 19206176

Male-to-male transmission of Costello syndrome: G12S HRAS germline mutation inherited from a father with somatic mosaicism.

Katia Sol-Church1, Deborah L Stabley, Laurie A Demmer, Abigail Agbulos, Angela E Lin, Leslie Smoot, Linda Nicholson, Karen W Gripp.   

Abstract

Costello syndrome is a rare congenital anomaly syndrome associated with mental retardation and predisposition to benign and malignant tumors, caused by heterozygous missense mutations in the HRAS oncogene. Previously, all molecularly analyzed mutations appeared de novo, and most arose in the paternal germline. A single patient with somatic mosaicism for a Costello syndrome causing HRAS mutation has been reported. Here we describe the first documented transmission of an HRAS mutation from a parent with somatic mosaicism to a child with typical Costello syndrome. Prior to the identification of the underlying gene mutation in Costello syndrome, this family had been identified clinically. The proband was subsequently found to carry a G12S HRAS germline mutation. Testing of the parents for parental origin identified his father as mosaic for the same HRAS mutation. The mother was found not to carry an HRAS mutation. The causative familial mutation is identified as a c.34G > A, which is the most common mutation in the HRAS gene in patients with Costello syndrome. The father carries the mutation in 7-8% of his alleles. This is the second case of mosaicism observed in Costello syndrome and the first direct molecular evidence of father-to-son transmission of the disease-causing mutation. Our observation underlines the importance of parental evaluation, and may have implications for genetic counseling and clinical practice. 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19206176      PMCID: PMC2653086          DOI: 10.1002/ajmg.a.32639

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  15 in total

1.  Recurring HRAS mutation G12S in Dutch patients with Costello syndrome.

Authors:  M A M van Steensel; M Vreeburg; C Peels; C M van Ravenswaaij-Arts; E Bijlsma; C T Schrander-Stumpel; M van Geel
Journal:  Exp Dermatol       Date:  2006-09       Impact factor: 3.960

2.  Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases.

Authors:  B Kerr; M-A Delrue; S Sigaudy; R Perveen; M Marche; I Burgelin; M Stef; B Tang; O B Eden; J O'Sullivan; A De Sandre-Giovannoli; W Reardon; C Brewer; C Bennett; O Quarell; E M'Cann; D Donnai; F Stewart; R Hennekam; H Cavé; A Verloes; N Philip; D Lacombe; N Levy; B Arveiler; G Black
Journal:  J Med Genet       Date:  2006-01-27       Impact factor: 6.318

3.  HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy.

Authors:  Anne L Estep; William E Tidyman; Michael A Teitell; Philip D Cotter; Katherine A Rauen
Journal:  Am J Med Genet A       Date:  2006-01-01       Impact factor: 2.802

4.  HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation.

Authors:  Karen W Gripp; Angela E Lin; Deborah L Stabley; Linda Nicholson; Charles I Scott; Daniel Doyle; Yoko Aoki; Yoichi Matsubara; Elaine H Zackai; Pablo Lapunzina; Antonio Gonzalez-Meneses; Jennifer Holbrook; Cynthia A Agresta; Iris L Gonzalez; Katia Sol-Church
Journal:  Am J Med Genet A       Date:  2006-01-01       Impact factor: 2.802

Review 5.  The diagnosis of Costello syndrome: nomenclature in Ras/MAPK pathway disorders.

Authors:  Bronwyn Kerr; Judith Allanson; Marie Ange Delrue; Karen W Gripp; Didier Lacombe; Angela E Lin; Katherine A Rauen
Journal:  Am J Med Genet A       Date:  2008-05-01       Impact factor: 2.802

Review 6.  Costello syndrome: phenotype, natural history, differential diagnosis, and possible cause.

Authors:  J P Johnson; M Golabi; M E Norton; R M Rosenblatt; G M Feldman; S P Yang; B D Hall; M H Fries; J C Carey
Journal:  J Pediatr       Date:  1998-09       Impact factor: 4.406

7.  Costello syndrome in two siblings and minor manifestations in their mother. Further evidence for autosomal dominant inheritance?

Authors:  D M Ioan; J P Fryns
Journal:  Genet Couns       Date:  2002

8.  Paternal bias in parental origin of HRAS mutations in Costello syndrome.

Authors:  Katia Sol-Church; Deborah L Stabley; Linda Nicholson; Iris L Gonzalez; Karen W Gripp
Journal:  Hum Mutat       Date:  2006-08       Impact factor: 4.878

9.  The adult phenotype in Costello syndrome.

Authors:  Susan M White; J M Graham; B Kerr; K Gripp; R Weksberg; C Cytrynbaum; J L Reeder; F J Stewart; M Edwards; M Wilson; A Bankier
Journal:  Am J Med Genet A       Date:  2005-07-15       Impact factor: 2.802

10.  Germline mutations in HRAS proto-oncogene cause Costello syndrome.

Authors:  Yoko Aoki; Tetsuya Niihori; Hiroshi Kawame; Kenji Kurosawa; Hirofumi Ohashi; Yukichi Tanaka; Mirella Filocamo; Kumi Kato; Yoichi Suzuki; Shigeo Kure; Yoichi Matsubara
Journal:  Nat Genet       Date:  2005-09-18       Impact factor: 38.330

View more
  19 in total

1.  Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome.

Authors:  Leopold Groesser; Eva Herschberger; Arno Ruetten; Claudia Ruivenkamp; Enrico Lopriore; Markus Zutt; Thomas Langmann; Sebastian Singer; Laura Klingseisen; Wulf Schneider-Brachert; Agusti Toll; Francisco X Real; Michael Landthaler; Christian Hafner
Journal:  Nat Genet       Date:  2012-06-10       Impact factor: 38.330

2.  Molecular confirmation of HRAS p.G12S in siblings with Costello syndrome.

Authors:  Karen W Gripp; Deborah L Stabley; Peter L Geller; Elizabeth Hopkins; David A Stevenson; John C Carey; Katia Sol-Church
Journal:  Am J Med Genet A       Date:  2011-08-10       Impact factor: 2.802

3.  Costello syndrome: Clinical phenotype, genotype, and management guidelines.

Authors:  Karen W Gripp; Lindsey A Morse; Marni Axelrad; Kathryn C Chatfield; Aaron Chidekel; William Dobyns; Daniel Doyle; Bronwyn Kerr; Angela E Lin; David D Schwartz; Barbara J Sibbles; Dawn Siegel; Suma P Shankar; David A Stevenson; Mihir M Thacker; K Nicole Weaver; Sue M White; Katherine A Rauen
Journal:  Am J Med Genet A       Date:  2019-06-20       Impact factor: 2.802

4.  C4ST-1/CHST11-controlled chondroitin sulfation interferes with oncogenic HRAS signaling in Costello syndrome.

Authors:  Michael Klüppel; Payman Samavarchi-Tehrani; Kela Liu; Jeffrey L Wrana; Aleksander Hinek
Journal:  Eur J Hum Genet       Date:  2012-02-08       Impact factor: 4.246

5.  Prenatal features of Costello syndrome: ultrasonographic findings and atrial tachycardia.

Authors:  Angela E Lin; Barbara O'Brien; Laurie A Demmer; Kristina K Almeda; Cynthia L Blanco; Patrick F Glasow; Charles I Berul; Robert Hamilton; A Micheil Innes; Julie L Lauzon; Katia Sol-Church; Karen W Gripp
Journal:  Prenat Diagn       Date:  2009-07       Impact factor: 3.050

6.  A novel HRAS substitution (c.266C>G; p.S89C) resulting in decreased downstream signaling suggests a new dimension of RAS pathway dysregulation in human development.

Authors:  Karen W Gripp; Eugenia Bifeld; Deborah L Stabley; Elizabeth Hopkins; Stefanie Meien; Kathy Vinette; Katia Sol-Church; Georg Rosenberger
Journal:  Am J Med Genet A       Date:  2012-07-20       Impact factor: 2.802

7.  Paternal uniparental disomy with segmental loss of heterozygosity of chromosome 11 are hallmark characteristics of syndromic and sporadic embryonal rhabdomyosarcoma.

Authors:  Katherine M Robbins; Deborah L Stabley; Jennifer Holbrook; Rebecca Sahraoui; Alexa Sadreameli; Katrina Conard; Laura Baker; Karen W Gripp; Katia Sol-Church
Journal:  Am J Med Genet A       Date:  2016-09-02       Impact factor: 2.802

8.  An attenuated phenotype of Costello syndrome in three unrelated individuals with a HRAS c.179G>A (p.Gly60Asp) mutation correlates with uncommon functional consequences.

Authors:  Karen W Gripp; Katia Sol-Church; Patroula Smpokou; Gail E Graham; David A Stevenson; Heather Hanson; David H Viskochil; Laura C Baker; Bridget Russo; Nick Gardner; Deborah L Stabley; Verena Kolbe; Georg Rosenberger
Journal:  Am J Med Genet A       Date:  2015-04-25       Impact factor: 2.802

Review 9.  Mosaic RASopathies.

Authors:  Christian Hafner; Leopold Groesser
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

10.  Germline and somatic mosaicism for FGFR2 mutation in the mother of a child with Crouzon syndrome: Implications for genetic testing in "paternal age-effect" syndromes.

Authors:  Anne Goriely; Helen Lord; Jasmine Lim; David Johnson; Tracy Lester; Helen V Firth; Andrew O M Wilkie
Journal:  Am J Med Genet A       Date:  2010-08       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.